SeekingAlpha
Although many equity markets slipped in January, they recovered over the next two months for a strong first quarter of 2024.
Yahoo
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the first quarter ended March 31, 2025. “The year is off to a great start. We believe RPT904 has the potential to be a best-in-class optio
Finnhub
RAPT Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported net loss was USD 17.17 million compared to USD 30.52 million a...
Yahoo
SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designe
Yahoo
SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March: Leerink Global Healthcare Conference – Fireside chat on Tuesday, March 11, 2
Yahoo
SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”) is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the fourth quarter and year ended December 31, 2024. “Our focus for 2025 will be on advancing development of RPT904, a novel, potentia
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -11.86% | $23.67B | +23.03% | 1.08% |
VIV | -10.94% | $15.90B | +14.91% | 0.00% |
CME | -10.28% | $100.13B | +32.10% | 3.76% |
LFVN | -9.41% | $166.79M | +85.06% | 1.23% |
PULM | -9.06% | $23.52M | +222.00% | 0.00% |
CIG | -9.01% | $3.54B | -5.31% | 0.00% |
TIMB | -8.98% | $8.43B | +8.44% | 2.93% |
CNTY | -8.91% | $60.75M | -30.04% | 0.00% |
XBIT | -8.20% | $90.55M | -66.02% | 0.00% |
SPTN | -7.93% | $676.92M | -3.15% | 4.42% |
REYN | -7.77% | $4.86B | -20.94% | 4.01% |
GO | -6.77% | $1.37B | -39.26% | 0.00% |
ICL | -6.47% | $8.48B | +39.49% | 2.90% |
MQ | -6.31% | $2.44B | -3.51% | 0.00% |
ED | -6.06% | $38.09B | +9.73% | 3.18% |
JHX | -5.95% | $10.63B | -20.20% | 0.00% |
LMT | -5.92% | $111.48B | +1.60% | 2.71% |
UTZ | -5.65% | $1.10B | -30.24% | 1.89% |
FIZZ | -5.64% | $4.27B | +5.69% | 0.00% |
LNT | -5.56% | $16.22B | +21.18% | 3.15% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ADM | -0.01% | $24.10B | -18.13% | 3.04% |
CMP | 0.02% | $818.26M | +47.93% | 0.00% |
NATR | 0.02% | $269.02M | -7.62% | 0.00% |
CVGW | 0.03% | $479.45M | +0.56% | 2.61% |
DG | -0.03% | $22.48B | -28.33% | 2.34% |
WRB | -0.04% | $27.90B | +41.90% | 0.49% |
MTCH | 0.04% | $7.21B | -2.03% | 1.29% |
BL | -0.09% | $3.45B | +5.24% | 0.00% |
FE | -0.11% | $24.66B | +5.69% | 4.03% |
HRL | -0.11% | $16.57B | -17.27% | 3.80% |
AMSF | -0.12% | $908.13M | +10.96% | 3.17% |
MGPI | 0.15% | $680.70M | -60.04% | 1.52% |
DSP | -0.16% | $916.60M | +52.52% | 0.00% |
HEES | -0.17% | $3.52B | +99.11% | 1.15% |
PARA | -0.18% | $8.00B | -1.90% | 1.69% |
MBI | -0.19% | $228.18M | -22.70% | 0.00% |
GALT | -0.19% | $81.65M | -60.06% | 0.00% |
CLX | 0.20% | $16.70B | +0.86% | 3.60% |
FATBB | -0.21% | $48.65M | -18.46% | 10.26% |
ERJ | 0.22% | $8.93B | +57.85% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -23.14% | $126.24M | 0.85% |
TAIL | -17.25% | $124.67M | 0.59% |
BTAL | -17.14% | $357.24M | 1.43% |
TPMN | -13.72% | $31.51M | 0.65% |
UNG | -11.95% | $337.71M | 1.06% |
TFLO | -9.51% | $7.00B | 0.15% |
BIL | -8.96% | $45.17B | 0.1356% |
FXY | -7.18% | $849.50M | 0.4% |
MEAR | -7.03% | $1.04B | 0.25% |
ULST | -6.93% | $632.19M | 0.2% |
CTA | -5.51% | $1.06B | 0.76% |
GBIL | -5.06% | $6.17B | 0.12% |
XONE | -5.00% | $608.43M | 0.03% |
SPTS | -4.98% | $5.74B | 0.03% |
AFIF | -4.15% | $134.15M | 1.11% |
BOXX | -3.89% | $6.28B | 0.19% |
BNDX | -3.86% | $65.10B | 0.07% |
FLDR | -3.65% | $858.66M | 0.15% |
JMST | -3.42% | $3.68B | 0.18% |
SGOV | -3.40% | $45.99B | 0.09% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBB | 34.02% | $5.25B | 0.45% |
XBI | 33.85% | $4.93B | 0.35% |
BBH | 31.87% | $331.37M | 0.35% |
PBE | 31.70% | $220.56M | 0.58% |
FBT | 30.59% | $1.03B | 0.56% |
GNOM | 29.51% | $40.81M | 0.5% |
VHT | 29.18% | $15.14B | 0.09% |
FHLC | 29.10% | $2.44B | 0.084% |
XLV | 27.71% | $34.95B | 0.09% |
IYH | 27.60% | $2.77B | 0.39% |
IXJ | 26.93% | $3.81B | 0.41% |
ARKG | 26.70% | $951.31M | 0.75% |
PINK | 26.67% | $132.14M | 0.5% |
XSD | 26.18% | $1.21B | 0.35% |
HEQT | 25.83% | $402.77M | 0.44% |
XPH | 25.73% | $140.11M | 0.35% |
ACIO | 25.73% | $1.87B | 0.79% |
HELO | 25.28% | $3.12B | 0.5% |
QFLR | 25.16% | $291.37M | 0.89% |
PTH | 25.14% | $99.23M | 0.6% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SMB | 0.01% | $269.36M | 0.07% |
SPMB | -0.03% | $5.92B | 0.04% |
GBTC | 0.03% | $19.55B | 1.5% |
BSCQ | -0.04% | $4.21B | 0.1% |
FXE | -0.04% | $514.85M | 0.4% |
FLMI | -0.05% | $662.37M | 0.3% |
XHLF | 0.06% | $1.46B | 0.03% |
STXT | 0.09% | $134.51M | 0.49% |
SCHZ | 0.11% | $8.51B | 0.03% |
IGOV | -0.11% | $976.17M | 0.35% |
BITO | 0.12% | $2.47B | 0.95% |
BILZ | 0.16% | $901.37M | 0.14% |
TLTW | 0.19% | $1.05B | 0.35% |
FBTC | 0.19% | $20.56B | 0.25% |
BTCW | 0.20% | $160.63M | 0.3% |
ARKB | 0.23% | $4.95B | 0.21% |
BITB | 0.23% | $3.97B | 0.2% |
DFSD | 0.24% | $4.50B | 0.16% |
EUSB | 0.24% | $685.37M | 0.12% |
IBIT | 0.24% | $65.72B | 0.25% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PLYA | 65.78% | $1.65B | +57.75% | 0.00% |
RUM | 57.42% | $3.27B | +32.28% | 0.00% |
AVXL | 42.47% | $642.85M | +73.10% | 0.00% |
HMC | 37.62% | $42.89B | -11.32% | 4.57% |
TLRY | 32.95% | $464.46M | -76.29% | 0.00% |
ABBV | 31.30% | $326.52B | +13.45% | 3.47% |
TPST | 30.19% | $24.67M | -84.66% | 0.00% |
RXRX | 29.66% | $1.85B | -52.16% | 0.00% |
KALV | 28.91% | $608.52M | +5.43% | 0.00% |
COHU | 28.86% | $825.89M | -39.45% | 0.00% |
GCMG | 27.80% | $626.43M | +24.68% | 3.53% |
ATXS | 27.62% | $242.10M | -53.37% | 0.00% |
GFS | 27.41% | $21.63B | -28.67% | 0.00% |
ALEC | 27.21% | $136.99M | -74.58% | 0.00% |
PDSB | 27.07% | $74.51M | -54.21% | 0.00% |
NVEC | 26.64% | $339.71M | -8.57% | 5.75% |
MPWR | 26.58% | $33.52B | -7.48% | 0.76% |
IPGP | 26.49% | $2.83B | -23.99% | 0.00% |
CTS | 26.38% | $1.26B | -22.10% | 0.38% |
SIMO | 26.18% | $2.19B | -17.10% | 3.14% |
Current Value
$0.931 Year Return
Current Value
$0.931 Year Return